Implantable endoderm organoids combine synthetic support structures and cells to repair or replace the function of endoderm-derived organs like the pancreas, liver, colon, stomach, intestines, lungs, and gall bladder. Adult cells are notoriously difficult to expand in vitro without loss of function, so many implants have harnessed new technologies based on induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs). Pioneers in the field are working to optimize cell lines and effectively scale manufacture protocols to transition to the clinic and fulfill the promise of these next generation of stem cell therapies.
Qkine appoints Japanese distribution partner MBL to extend global availability of its innovative stem cell and organoid culture reagents
Qkine has concluded a sales distribution agreement with Japanese company, MBL Medical & Biological Laboratories Co., Ltd. MBL have extensive knowledge and presence within the Japanese regenerative medicine and iPSC sector, an important market for Qkine's high purity, animal-free optimised growth factor and cytokine proteins. The two companies share a focus on product quality and the emerging areas of organoid and organ-on-chip technologies for basic research, personalised medicine and drug discovery. This distributor agreement between Qkine and MBL will facilitate access to Qkine's entire range of premium quality, animal-free and novel optimised growth factor proteins across Japan.